Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919380 | 0.80 | RAB9A (0.40) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4870462 | 0.76 | — | — | |
| SCHEMBL5483645 | 0.76 | ALDH1A1 (0.55) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL31115164 | 0.76 | ALDH1A1 (0.55) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL2459241 | 0.76 | NPC1 (0.41) | KDM4EGPR3ALDH1A1MAPTHPGD | |
| SCHEMBL6247283 | 0.76 | KDM4E (0.41) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL317014 | 0.75 | GPR3 (0.41) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL31268563 | 0.73 | HTR2C (0.43) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL184194 | 0.72 | KDM4E (0.38) | KDM4EGPR3ALDH1A1GLAMAPT | |
| SCHEMBL18806848 | 0.70 | KDM4E (0.48) | KDM4EGPR3ALDH1A1GLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007501804-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | claimed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | claimed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | claimed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| US-10989710-B2 | Identifying new therapeutic agents | Revolution Medicines, Inc. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190271691-A1 | IDENTIFYING NEW THERAPEUTIC AGENTS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-09-05 | — | — | US | disclosed |
| US-9452215-B2 | Bourvadin derivatives and therapeutic uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2015-08-27 | — | — | US | disclosed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2327701-A1 | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
| US-4820842-A | 2-substituted-1,4-dihydropyridines | WARNER-LAMBERT COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | KDM4E 3398/4885GPR3 746/4885ALDH1A1 1244/4885 |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885GPR3 1346/4885ALDH1A1 2811/4885 |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885GPR3 1346/4885ALDH1A1 2811/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885GPR3 1346/4885ALDH1A1 2811/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885GPR3 1346/4885ALDH1A1 2811/4885 |
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | RPL27, EIF4E, RPL30 | KDM4E 526/4885GPR3 3576/4885ALDH1A1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.